JPMorgan analyst Richard Vosser lowered the firm’s price target on Molecular Partners (MOLN) to $4 from $4.50 and keeps a Neutral rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
- Promising Developments and Strategic Resource Management Justify Buy Rating for Molecular Partners AG
- Molecular Partners AG Reports H1 2025 Progress
- Molecular Partners’ Promising Pipeline and Strategic Advancements Justify Buy Rating
- Molecular Partners Advances Clinical Programs and Strengthens Financial Position in H1 2025